WBMT ACTIVITY SURVEY ON CELLULAR THERAPY

Report the number of **patients** receiving their 1st non HCT cellular therapies by indication and cell type.

Enter the name of the center reporting OR if at the country level, the name of the country and the number of centers that have reported data.

Year of data collection:	
Name of country or center:	
If country level, number of reporting centers:	

Nunmber of patients with non HSCT Cellular therapies using manipulated or selected cells (excluding DLI)	CAR T cells		selected/expanded T cells or CIK		Regulatory T cells (TREGS)		Other genetically modified T cells		Natural Killer cells		Dendritic cells		MSC		Expanded CD34+ cells		Genetically modified CD34+		Other therapies (incl. boosts)		TOTAL	
	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto
GvHD																						
Graft enhancement/failure																						
Autoimmune disease																						
Genetic disease																						
Infection																						
Malignancy - Acute lymphocytic leukemia																						
Malignancy - Lymphoma																						
Malignancy - Myeloma																						
Malignancy - Solid tumors																						
Any other indication																						
TOTAL																						

Number of patients receiving Non-HCT Cellular Therapies in your country or centre.

Guidelines

Report the annual number of **patients** receiving their 1st NON-HCT cellular therapies in your country or centre by indication and cell type for which the therapy is given.

Report both patients with or without transplants. Patients in clinical trials may also be reported.

Note: CD34+ selected transplants or for example CD3+/CD19+ deleted cell infusions are to be reported as transplants.

CAR T cells: T cells that are genetically modified by viral or non-viral vector to express chimeric antigen receptors or T cell receptors.

Selected/expanded T cells or Cytokine Induced Killer cells (CIK): non genetically modified T cells selected, expanded in vitro or cytokine activated. This includes all manipulated T cell infusions, with either positive or negative selection.

Regulatory T cells (TREGS): T cells that are processed after harvesting by selecting for the subset of regulatory T cells.

Other genetically modified T cells: other genetically modified T cells with suicide genes or other genes.

Natural Killer cells (NK cells): cells that are processed after harvesting by selecting for NK cells with or without expansion or genetic modification.

Dendritic cells: antigen presenting cells that are used for tumour cell vaccination and other purposes.

Mesenchymal Stromal Cells (MSC):. Expanded CD34+ cells: stem cell products that are expanded in vitro prior to infusion to the patient.

Genetically modified CD34+ cells: genetically modified stem cells, typically used for congenital diseases.

Other therapies: allogeneic or autologous boosts and any other cellular therapies not listed above.